Literature DB >> 17134757

Direct impact of inactivated HIV-1 virions on B lymphocyte subsets.

Muriel Viau1, Francisco Veas, Moncef Zouali.   

Abstract

Although there is no convincing evidence that HIV infects primary B cells, marked changes in B cell responses have been described in HIV-1-infected subjects, including B cell repertoire perturbations, depression of B cell memory and paucity of CD5(+) B cells. As it is hard to assess the consequences of these in vitro and ex vivo observations in patients, the pathogenic mechanisms responsible for the B cell deficit are unclear, and direct and indirect effects of HIV-1 remain possible. To gain further insight into the impact of HIV-1 on the B cell compartment in vivo, we used XenoMouse mice, mice genetically engineered to express human antibodies with an absence of mouse antibody expression. In these transgenic animals, B cells expressing a virtually full human Ig repertoire develop, which allows investigation of the in vivo consequences of confronting B cells expressing human immunoglobulins with HIV-1. We found that soluble gp120 induced an inversion in the B-1a/B-1b cell ratios, without impacting B-2 cells or affecting substantially the T cell compartment. Virion treatment specifically and dramatically depressed B-1a cells, which represent the majority of B-1 cells in normal mice. The observed B cell changes were associated with a functional alteration of the humoral response to tetanus toxoid. Thus, the results reveal a capacity of HIV-1 to specifically impact a highly specialized B cell subpopulation. Because there is evidence that human IgM memory B cells are functionally equivalent to murine B-1a cells, our findings suggest that gp120 may have a direct deleting activity on B cell memory.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17134757     DOI: 10.1016/j.molimm.2006.07.302

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  9 in total

1.  T cell responses of HIV-infected children after administration of inactivated or live attenuated influenza vaccines.

Authors:  Adriana Weinberg; Lin-Ye Song; Terence Fenton; Sharon A Nachman; Jennifer S Read; Julie Patterson-Bartlett; Myron J Levin
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

2.  IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine.

Authors:  Sanghita Sarkar; Michael S Piepenbrink; Madhubanti Basu; Juilee Thakar; Michael C Keefer; Ann J Hessell; Nancy L Haigwood; James J Kobie
Journal:  Vaccine       Date:  2019-03-27       Impact factor: 3.641

3.  Virologic and immunologic correlates with the magnitude of antibody responses to the hepatitis A vaccine in HIV-infected children on highly active antiretroviral treatment.

Authors:  Adriana Weinberg; Sharon Huang; Terence Fenton; Julie Patterson-Bartlett; Philimon Gona; Jennifer S Read; Wayne M Dankner; Sharon Nachman
Journal:  J Acquir Immune Defic Syndr       Date:  2009-09-01       Impact factor: 3.731

4.  Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease.

Authors:  Felix Breden; Christa Lepik; Nancy S Longo; Marinieve Montero; Peter E Lipsky; Jamie K Scott
Journal:  PLoS One       Date:  2011-03-30       Impact factor: 3.240

5.  Characterization of functional antibody and memory B-cell responses to pH1N1 monovalent vaccine in HIV-infected children and youth.

Authors:  Donna J Curtis; Petronella Muresan; Sharon Nachman; Terence Fenton; Kelly M Richardson; Teresa Dominguez; Patricia M Flynn; Stephen A Spector; Coleen K Cunningham; Anthony Bloom; Adriana Weinberg
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

6.  Determinants of vaccine immunogenicity in HIV-infected pregnant women: analysis of B and T cell responses to pandemic H1N1 monovalent vaccine.

Authors:  Adriana Weinberg; Petronella Muresan; Kelly M Richardson; Terence Fenton; Teresa Dominguez; Anthony Bloom; D Heather Watts; Mark J Abzug; Sharon A Nachman; Myron J Levin
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

Review 7.  Role of the Fas/FasL pathway in HIV or SIV disease.

Authors:  Bhawna Poonia; C David Pauza; Maria S Salvato
Journal:  Retrovirology       Date:  2009-10-15       Impact factor: 4.602

8.  Marginal zone B-cells, a gatekeeper of innate immunity.

Authors:  Moncef Zouali; Yolande Richard
Journal:  Front Immunol       Date:  2011-12-13       Impact factor: 7.561

9.  Mice with a human touch.

Authors:  Christopher Thomas Scott
Journal:  Nat Biotechnol       Date:  2007-10       Impact factor: 54.908

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.